Información del producto
- 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-
- 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline
- Canertinib base
- Cl 1033
- N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide
- N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide
- N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[2-(morpholin-4-yl)ethoxy]quinazolin-6-yl}prop-2-enamide
- N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide
Canertinib is a small molecule that inhibits the protein synthesis of cancer cells by inhibiting the epidermal growth factor receptor (EGFR). It has been shown to have therapeutic effects against lung, brain, and breast cancers. Canertinib also binds to the EGFR monoclonal antibodies, which are used in cancer immunotherapy. This drug has been shown to inhibit the growth of human osteosarcoma cells in vitro and in vivo. Canertinib has also been shown to inhibit fatty acid synthesis and cell signaling pathways that regulate cancer cell growth.
Propiedades químicas
Consulta técnica sobre: 3D-SKA24328 Canertinib (CI-1033)
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
